Influenza Vaccine Market Size, Share & Analysis Report, 2023-2032
The global Influenza Vaccine market size was exhibited at USD 7.35 billion in 2022 and is projected to hit around USD 14.24 billion by 2032, growing at a CAGR of 6.84% during the forecast period 2023 to 2032.
Key Pointers:
Influenza Vaccine Market Report Scope
|
Report Coverage |
Details |
|
Market Size in 2023 |
USD 7.85 Billion |
|
Market Size by 2032 |
USD 14.24 Billion |
|
Growth Rate from 2023 to 2032 |
CAGR of 6.84% |
|
Base year |
2022 |
|
Forecast period |
2023 to 2032 |
|
Segments covered |
Vaccine type, Indication, Age group, Distribution channel, Route of administration |
|
Regional scope |
North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
|
Key companies profiled |
GSK plc; AstraZeneca; SINOVAC, Pfizer Inc; Vaxess Technologies Inc; CSL Limited; EMERGENT; Merck & Co., Inc.; Viatris Inc.; OSIVAX; EMERGEX VACCINES |
The rise in the incidences of seasonal influenza and increasing recommendations for vaccination against the disease is anticipated to increase the sales of vaccines. According to the CDC’s estimates of December 2022, there have been at least 15 million new cases of influenza with around 9,300 deaths and over 150,000 hospitalizations. In addition, the surge in surveillance and government support regarding influenza vaccination at country and global levels for monitoring the distribution, supply, and administration of the vaccine is one of the key drivers of growth in the market.
The increasing government initiatives to support influenza vaccination is one of the major factors propelling the global market growth. In association with other government bodies, the WHO steadily monitors the demand and conducts vaccination programs across the globe to manage the unmet need for vaccination. For instance, in July 2022, the government of Manitoba, Canada announced an expansion of eligibility for the high-dose influenza vaccine to include adults aged 65 years and above for enhanced protection from a life-threatening infection.
Moreover, there are many licensed seasonal influenza vaccines put forward by CDC, WHO, and other regulatory bodies to combat the infection in the current market scenario. In addition, governments around the world recommend people get immunized to attain maximum protection against diseases like the flu. Moreover, in September 2022, the Advisory Committee on Immunization Practices (ACIP) recommended the influenza vaccine to all people aged above 6 months, especially people with acute COVID-19 disease.
In addition, the increase in R&D investments by leading vaccine manufacturers and the presence of robust investigational pipeline products are anticipated to support market growth. For instance, the key pipeline products in various stages of development include mRNA-1010, OVX836, INNA-051, DAS181, OVX836, UniFlu, AV5080, ALVR106, GSK3206641A, and others.
The investigational candidates are showing promising effects with enhanced safety and protection against infection. For instance, in April 2022, Novavax, Inc. announced phase I/II results of its COVID-19 and influenza combination vaccine. The results show the vaccine is well tolerated and feasible.
Increasing investment to expand the production of influenza vaccines across the globe will boost the adoption of the vaccine. For instance, in June 2022, CSL Seqirus announced the completion of a USD 156 million expansion at its production facility in the U.S. This expansion is expected to support the formulation of its cell-based influenza vaccines in pre-filled syringes. Moreover, in March 2021, Sanofi invested USD 679 million in a new vaccine manufacturing facility in Toronto. This investment facilitated the filling capacity for Sanofi’s quadrivalent flu vaccine and boosted the supply chain in Canada, and Europe.
Influenza Vaccine Market Segmentation
| By Vaccine Type | By Indication | By Age Group | By Route of Administration | By Distribution Channel |
|
|
|
|
|
Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment scope
1.1.2 Regional scope
1.1.3 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database:
1.3.2 Nova one advisor’s internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective 1
1.10.2 Objective 2
1.10.3 Objective 3
1.10.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Competitive Insights
Chapter 3 Influenza Vaccine Market Variables, Trends, & Scope
3.1 Market Lineage Outlook
3.1.1 Parent market
3.2 Market Dynamics
3.2.1 Market drivers analysis
3.2.1.1 Increase in prevalence of influenza
3.2.1.2 Active government support to promote vaccinations
3.2.2 Market restraint analysis
3.2.2.1 Longer timeline for vaccine production
3.3 Penetration & Growth Prospect Mapping
3.4 Influenza Vaccine: Market Analysis Tools
3.4.1 Industry analysis - Porter’s
3.4.2 PESTLE analysis
3.5 Regulatory Framework
3.6 Pricing Analysis
Chapter 4 Influenza Vaccine Market Segment Analysis, By Vaccine Type, 2020 - 2032
4.1 Definition and Scope
4.2 Vaccine Type Market Share Analysis, 2023 & 2032
4.3 Segment Dashboard
4.4 Global Influenza Vaccine Market, by Vaccine Type, 2020 to 2032
4.5 Market Size & Forecasts and Trend Analyses, 2020 to 2032
4.5.1 Inactivated
4.5.1.1 Inactivated market estimates and forecast, 2020 - 2032
4.5.2 Live Attenuated
4.5.2.1 Live Attenuated market estimates and forecast, 2020 - 2032
Chapter 5 Influenza Vaccine Market Segment Analysis, By Indication 2020 - 2032
5.1 Definition and Scope
5.2 Indication Market Share Analysis, 2023 & 2032
5.3 Segment Dashboard
5.4 Global Influenza Vaccine Market, by Indication, 2020 to 2032
5.5 Market Size & Forecasts and Trend Analyses, 2020 to 2032
5.5.1 Quadrivalent
5.5.1.1 Quadrivalent market estimates and forecast, 2020 - 2032
5.5.2 Trivalent
5.5.2.1 Trivalent market estimates and forecast, 2020 - 2032
Chapter 6 Influenza Vaccine Market Segment Analysis, By Route of Administration, 2020 - 2032
6.1 Definition and Scope
6.2 Route of Administration Market Share Analysis, 2023 & 2032
6.3 Segment Dashboard
6.4 Global Influenza Vaccine Market, by Route of Administration, 2020 to 2032
6.5 Market Size & Forecasts and Trend Analyses, 2020 to 2032
6.5.1 Injection
6.5.1.1 Injection market estimates and forecast, 2020 - 2032
6.5.2 Nasal Spray
6.5.2.1 Nasal Spray market estimates and forecast, 2020 - 2032
Chapter 7 Influenza Vaccine Market Segment Analysis, By Age Group, 2020 - 2032
7.1 Definition and Scope
7.2 Age Group Market Share Analysis, 2023 & 2032
7.3 Segment Dashboard
7.4 Global Influenza Vaccine Market, by Age Group, 2020 to 2032
7.5 Market Size & Forecasts and Trend Analyses, 2020 to 2032
7.5.1 Pediatric
7.5.1.1 Pediatric market estimates and forecast, 2020 - 2032
7.5.2 Adult
7.5.2.1 Adult market estimates and forecast, 2020 - 2032
Chapter 8 Influenza Vaccine Market Segment Analysis, By Distribution channel, 2020 - 2032
8.1 Definition and Scope
8.2 Distribution Channel Market Share Analysis, 2023 & 2032
8.3 Segment Dashboard
8.4 Global Influenza Vaccine Market, by Distribution Channel, 2020 to 2032
8.5 Market Size & Forecasts and Trend Analyses, 2020 to 2032
8.5.1 Hospitals & Pharmacy
8.5.1.1 Hospitals & Pharmacy market estimates and forecast, 2020 - 2032
8.5.2 Government & Institutional Supply
8.5.2.1 Government & Institutional Supply market estimates and forecast, 2020 - 2032
8.5.3 Other
8.5.3.1 Other market estimates and forecast, 2020 - 2032
Chapter 9 Influenza Vaccine Market Segment Analysis, By Region, 2020 - 2032
9.1 Definition & Scope
9.2 Regional Market Share Analysis, 2023 & 2032
9.3 Regional Market Dashboard
9.4 Regional Market Snapshot
9.5 SWOT Analysis
9.5.1 North America
9.5.2 Europe
9.5.3 Asia Pacific
9.5.4 Latin America
9.5.5 Middle East and Africa
9.6 Market Size, & Forecasts, Revenue and Trend Analysis, 2023 to 2032
9.6.1 North America
9.6.1.1 North America influenza vaccine market, 2020 - 2032
9.6.1.2 U.S.
9.6.1.2.1 Key Country Dynamics
9.6.1.2.2 Competitive Scenario
9.6.1.2.3 Regulatory Framework
9.6.1.2.4 Reimbursement Scenario
9.6.1.2.5 U.S. market estimates and forecast, 2020 - 2032
9.6.1.3 Canada
9.6.1.3.1 Key Country Dynamics
9.6.1.3.2 Competitive Scenario
9.6.1.3.3 Regulatory Framework
9.6.1.3.4 Reimbursement Scenario
9.6.1.3.5 Canada market estimates and forecast, 2020 - 2032
9.6.2 Europe
9.6.2.1 Europe influenza vaccine market, 2020 - 2032
9.6.2.2 U.K.
9.6.2.2.1 Key Country Dynamics
9.6.2.2.2 Competitive Scenario
9.6.2.2.3 Regulatory Framework
9.6.2.2.4 Reimbursement Scenario
9.6.2.2.5 U.K. market estimates and forecast, 2020 - 2032
9.6.2.3 Germany
9.6.2.3.1 Key Country Dynamics
9.6.2.3.2 Competitive Scenario
9.6.2.3.3 Regulatory Framework
9.6.2.3.4 Reimbursement Scenario
9.6.2.3.5 Germany market estimates and forecast, 2020 - 2032
9.6.2.4 Spain
9.6.2.4.1 Key Country Dynamics
9.6.2.4.2 Competitive Scenario
9.6.2.4.3 Regulatory Framework
9.6.2.4.4 Reimbursement Scenario
9.6.2.4.5 Spain market estimates and forecast, 2020 - 2032
9.6.2.5 France
9.6.2.5.1 Key Country Dynamics
9.6.2.5.2 Competitive Scenario
9.6.2.5.3 Regulatory Framework
9.6.2.5.4 Reimbursement Scenario
9.6.2.5.5 France market estimates and forecast, 2020 - 2032
9.6.2.6 Italy
9.6.2.6.1 Key Country Dynamics
9.6.2.6.2 Competitive Scenario
9.6.2.6.3 Regulatory Framework
9.6.2.6.4 Reimbursement Scenario
9.6.2.6.5 Italy market estimates and forecast, 2020 - 2032
9.6.2.7 Denmark
9.6.2.7.1 Key Country Dynamics
9.6.2.7.2 Competitive Scenario
9.6.2.7.3 Regulatory Framework
9.6.2.7.4 Reimbursement Scenario
9.6.2.7.5 Denmark market estimates and forecast, 2020 - 2032
9.6.2.8 Sweden
9.6.2.8.1 Key Country Dynamics
9.6.2.8.2 Competitive Scenario
9.6.2.8.3 Regulatory Framework
9.6.2.8.4 Reimbursement Scenario
9.6.2.8.5 Sweden market estimates and forecast, 2020 - 2032
9.6.2.9 Norway
9.6.2.9.1 Key Country Dynamics
9.6.2.9.2 Competitive Scenario
9.6.2.9.3 Regulatory Framework
9.6.2.9.4 Reimbursement Scenario
9.6.2.9.5 Norway market estimates and forecast, 2020 - 2032
9.6.3 Asia Pacific
9.6.3.1 Asia Pacific influenza vaccine market, 2020 - 2032
9.6.3.2 Japan
9.6.3.2.1 Key Country Dynamics
9.6.3.2.2 Competitive Scenario
9.6.3.2.3 Regulatory Framework
9.6.3.2.4 Reimbursement Scenario
9.6.3.2.5 Japan market estimates and forecast, 2020 - 2032
9.6.3.3 China
9.6.3.3.1 Key Country Dynamics
9.6.3.3.2 Competitive Scenario
9.6.3.3.3 Regulatory Framework
9.6.3.3.4 Reimbursement Scenario
9.6.3.3.5 China market estimates and forecast, 2020 - 2032
9.6.3.4 India
9.6.3.4.1 Key Country Dynamics
9.6.3.4.2 Competitive Scenario
9.6.3.4.3 Regulatory Framework
9.6.3.4.4 Reimbursement Scenario
9.6.3.4.5 India market estimates and forecast, 2020 - 2032
9.6.3.5 South Korea
9.6.3.5.1 Key Country Dynamics
9.6.3.5.2 Competitive Scenario
9.6.3.5.3 Regulatory Framework
9.6.3.5.4 Reimbursement Scenario
9.6.3.25.5 South Korea market estimates and forecast, 2020 - 2032
9.6.3.6 Australia
9.6.3.6.1 Key Country Dynamics
9.6.3.6.2 Competitive Scenario
9.6.3.6.3 Regulatory Framework
9.6.3.6.4 Reimbursement Scenario
9.6.3.6.5 Australia market estimates and forecast, 2020 - 2032
9.6.3.7 Thailand
9.6.3.7.1 Key Country Dynamics
9.6.3.7.2 Competitive Scenario
9.6.3.7.3 Regulatory Framework
9.6.3.7.4 Reimbursement Scenario
9.6.3.7.5 Thailand market estimates and forecast, 2020 - 2032
9.6.4 Latin America
9.6.4.1 Latin America influenza vaccine market, 2020 - 2032
9.6.4.2 Brazil
9.6.4.2.1 Key Country Dynamics
9.6.4.2.2 Competitive Scenario
9.6.4.2.3 Regulatory Framework
9.6.4.2.4 Reimbursement Scenario
9.6.4.2.5 Brazil market estimates and forecast, 2020 - 2032
9.6.4.3 Mexico
9.6.4.3.1 Key Country Dynamics
9.6.4.3.2 Competitive Scenario
9.6.4.3.3 Regulatory Framework
9.6.4.3.4 Reimbursement Scenario
9.6.4.3.5 Mexico market estimates and forecast, 2020 - 2032
9.6.4.4 Argentina
9.6.4.4.1 Key Country Dynamics
9.6.4.4.2 Competitive Scenario
9.6.4.4.3 Regulatory Framework
9.6.4.4.4 Reimbursement Scenario
9.6.4.4.5 Argentina market estimates and forecast, 2020 - 2032
9.6.5 MEA
9.6.5.1 MEA influenza vaccine market, 2020 - 2032
9.6.5.2 South Africa
9.6.5.2.1 Key Country Dynamics
9.6.5.2.2 Competitive Scenario
9.6.5.2.3 Regulatory Framework
9.6.5.2.4 Reimbursement Scenario
9.6.5.2.5 South Africa market estimates and forecast, 2020 - 2032
9.6.5.3 Saudi Arabia
9.6.5.3.1 Key Country Dynamics
9.6.5.3.2 Competitive Scenario
9.6.5.3.3 Regulatory Framework
9.6.5.3.4 Reimbursement Scenario
9.6.5.3.5 Saudi Arabia market estimates and forecast, 2020 - 2032
9.6.5.4 UAE
9.6.5.4.1 Key Country Dynamics
9.6.5.4.2 Competitive Scenario
9.6.5.4.3 Regulatory Framework
9.6.5.4.4 Reimbursement Scenario
9.6.5.4.5 UAE market estimates and forecast, 2020 - 2032
9.6.5.5 Kuwait
9.6.5.5.1 Key Country Dynamics
9.6.5.5.2 Competitive Scenario
9.6.5.5.3 Regulatory Framework
9.6.5.5.4 Reimbursement Scenario
9.6.5.5.5 Kuwait market estimates and forecast, 2020 - 2032
Chapter 10 Influenza Vaccine Market - Competitive Analysis
10.1 Recent Developments & Impact Analysis, by Key Market Participants
10.1.1 Ansoff matrix
10.1.2 Heat map analysis
10.1.3 Major Deals and Strategic Alliances Analysis
10.1.3.1 Joint Ventures
10.1.3.2 Licensing Agreements
10.1.3.3 Product Launches
10.1.3.4 Conferences and Campaigns
10.2 Company Categorization
10.2.1 Innovators
10.2.2 Market Leaders
10.3 Vendor Landscape
10.3.1 List of key distributors and channel partners
10.3.2 Key customers
10.4 Public Companies
10.4.1 Competitive Dashboard Analysis
10.4.1.1 Market Differentiators
10.5 Private Companies
10.5.1 List of key emerging companies
10.6 Company Profiles
10.6.1 GSK plc
10.6.1.1 Company overview
10.6.1.2 Financial performance
10.6.1.3 Product benchmarking
10.6.1.4 Strategic Initiatives
10.6.2 AstraZeneca
10.6.2.1 Company overview
10.6.2.2 Financial performance
10.6.2.3 Product benchmarking
10.6.2.4 Strategic Initiatives
10.6.3 SINOVAC
10.6.3.1 Company overview
10.6.3.2 Financial performance
10.6.3.3 Product benchmarking
10.6.3.4 Strategic Initiatives
10.6.4 Vaxess Technologies Inc
10.6.4.1 Company overview
10.6.4.2 Financial performance
10.6.4.3 Product benchmarking
10.6.4.4 Strategic Initiatives
10.6.5 Pfizer Inc
10.6.5.1 Company overview
10.6.5.2 Financial performance
10.6.5.3 Product benchmarking
10.6.5.4 Strategic Initiatives
10.6.6 CSL Limited
10.6.6.1 Company overview
10.6.6.2 Financial performance
10.6.6.3 Product benchmarking
10.6.6.4 Strategic Initiatives
10.6.7 EMERGENT
10.6.7.1 Company overview
10.6.7.2 Financial performance
10.6.7.3 Product benchmarking
10.6.7.4 Strategic initiatives
10.6.8 Merck & Co., Inc.
10.6.8.1 Company overview
10.6.8.2 Financial performance
10.6.8.3 Product benchmarking
10.6.8.4 Strategic initiatives
10.6.9 Viatris Inc.
10.6.9.1 Company overview
10.6.9.2 Financial performance
10.6.9.3 Product benchmarking
10.6.9.4 Strategic initiatives
10.6.10 OSIVAX, EMERGEX VACCINES
10.6.10.1 Company overview
10.6.10.2 Financial performance
10.6.10.3 Product benchmarking
10.6.10.4 Strategic initiatives
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers